--- title: Next-Generation At-Line Cell Culture Media Analysis Enables Real-Time Data-Driven Optimization description: This webinar explores how at-line media analysis enables rapid, quantitative profiling of amino acids and key nutrients across upstream workflows. --- [![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/) # ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png) # Next-Generation At-Line Cell # Culture Media Analysis Enables # Real-Time Data-Driven Optimization |   | | --- | ## Presenters:   ****![06-26-2025-908-Devices-Bell-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/06-26-2025-908-Devices-Bell-HS-Cropped.jpg?width=150&height=213&name=06-26-2025-908-Devices-Bell-HS-Cropped.jpg)**Ashley Bell** *Associate Director Key Accounts & FAS,* Repligen   Ashley Bell is the associate director, key sccounts & field application scientists (FAS) at Repligen, where she leads the strategy and execution of technical engagement for the process analytical technology (PAT) upstream portfolio. With more than 15 years of experience in protein chemistry and mass spectrometry, Ashley is widely respected for her ability to translate analytical innovation into practical solutions for upstream bioprocessing. Ashley has held scientific roles across leading research institutions and biopharmaceutical companies, including The Institute for Systems Biology, Amgen, and Bristol-Myers Squibb. Her work has focused on applying high-resolution analytical techniques to solve complex challenges in proteomics, product characterization, and process development. She has contributed to the development and optimization of biologics pipelines at multiple stages, from early discovery to late-phase development. In her current role, Ashley works closely with key biopharma accounts and leads a global team of field application scientists. Her team supports the implementation of real-time, at-line analytical technologies to advance upstream process understanding, optimize cell culture conditions, and accelerate decision-making. Her scientific credibility and ability to connect bench-level science with business impact make her a strong advocate for broader PAT adoption. Ashley earned her bachelor's degree in chemistry from California State University, Bakersfield. She has received multiple recognitions throughout her career, including the Doris A. Howell Foundation Award for Women’s Health Research and several innovation awards at Amgen for her contributions to product pipeline advancement. She is a contributing author on peer-reviewed publications and is known across the industry for her collaborative, science-first approach to technical leadership   ****![06-26-2025-908-Devices-Miller-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/06-26-2025-908-Devices-Miller-HS-Cropped.jpg?width=150&height=221&name=06-26-2025-908-Devices-Miller-HS-Cropped.jpg)**Scott Miller, PhD** *Director of Instrument Development,* Repligen   Scott Miller, PhD is director of instrument development at Repligen, where he leads innovation efforts focused on process analytical technology (PAT) and enhancing the customer experience across Repligen’s growing portfolio of analytical instruments. With over 20 years of experience developing groundbreaking technologies in mass spectrometry, bioprocess analytics, and system integration, Scott brings deep technical expertise and a passion for translating complex science into intuitive, impactful tools for end users. Scott was a co-founder of 908 Devices, where he helped pioneer miniaturized mass spectrometry systems and led application development and engineering teams that brought powerful analytical platforms into both field and bioprocessing environments. He played a critical role in launching solutions that have redefined speed and simplicity in real-time bioprocess analysis. Prior to 908 Devices, Scott held senior technical roles at Ahura Scientific and Thermo Fisher Scientific, where he led several high-profile, government-funded R&D programs focused on portable chemical and biological detection. He also served as principal scientist at BioProcessors Corporation, developing automated microscale cell culture systems that laid the groundwork for early bioprocess intensification strategies. Scott earned his doctoral degree in physical chemistry from Northwestern University and completed his postdoctoral research at MIT, where he further honed his interdisciplinary approach to innovation. He is the author of numerous peer-reviewed publications and holds multiple patents in analytical instrumentation and bioprocessing technologies. At Repligen, Scott continues to bridge cutting-edge science with practical engineering to advance PAT adoption and deliver smart, user-centered solutions that empower biopharmaceutical manufacturers to optimize performance, ensure quality, and accelerate development.   ****![06-26-2025-908-Devices-Barbau-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/06-26-2025-908-Devices-Barbau-HS-Cropped.jpg?width=150&height=214&name=06-26-2025-908-Devices-Barbau-HS-Cropped.jpg)**Jérémie Barbau** *Senior Application Scientist,* Repligen   Jérémie Barbau works as a senior application scientist at Repligen. He is a customer-facing expert with proficiency in bioprocessing who bridges the gap between product development and market adoption, ensuring customer success through deep technical knowledge and hands-on implementation.   Before joining Repligen, he held a position of bioprocessing expert, field applications at 908devices. For the last 20 years, he has worked at various positions/levels in the biopharmaceutical process development world, for companies ranging from well established pharmaceutical companies to smaller, startup-like structures, giving him a broad overview of the challenges and solutions specific to the biopharmaceutical industry.   ## About this event: #### Date: June 26, 2025 #### Time: 11 am EDT | 8 am PDT | 5 pm CEST #### Duration: 30 minutes | Precise characterization of amino acid profiles in cell culture media is fundamental to understanding and controlling upstream performance. Amino acids play a central role in cell metabolism, viability, and productivity, with significant influence on growth dynamics and critical quality attributes (CQAs) such as glycosylation and titer. However, delays in accessing nutrient data—typical of conventional analytical workflows—can hinder timely decision-making and slow process development. This webinar explores how at-line media analysis enables rapid, quantitative profiling of amino acids and key nutrients across upstream workflows—from verifying media composition and optimizing feed strategies to monitoring bioreactor performance and supporting scale-down model development. By reducing turnaround from days or weeks to minutes, this approach empowers scientists to respond to nutrient shifts in real time. Key Takeaways: - Understand how amino acid and nutrient profiling in real time can inform feed strategies, maintain cell health, and improve product quality. - Learn how at-line media analysis reduces reliance on core lab testing to accelerate upstream development and process decision-making. - Explore the enhanced features of the new REBEL® XT System that deliver faster, broader, and more user-friendly media analysis. | | --- | -   -   ©2015 BioProcess International All Rights reserved